Avant Healthcare is a medical marketing communications agency that focuses on the education and engagement of healthcare professionals. For the past 20 years, Avant Healthcare has partnered with pharmaceutical, biotechnology, diagnostic, and medical device companies, including the support of multibillion dollar brands, from prelaunch through product expiration. Whether working from a promotional or nonpromotional standpoint, we increase our clients’ effectiveness by combining best-in-class strategy, curriculum development, technology, and creative design to deliver high-impact, high-quality medical education and measurable results.
With more than 180 staff members, Avant Healthcare is a certified diversity supplier (Women’s Business Enterprise National Council) based in Carmel, Indiana, with remote teams in the Los Angeles and Chicago areas. Key services include Medical Storytelling (creative content development that is compelling and memorable); KOL Strategy and Management (matching the best experts to fulfill business needs); and Integrated Customer Experiences (positively reinforcing key messages at every customer touch point: before, during, and after content delivery).
- Company Resources
Video Conference Case Study
Avant Healthcare was approached with a challenge: How to "wow" the field sales force by developing new programming that is easy, effective, and cost-efficient. Take a look at this case study infographic to see the results.
TL Engagement and the Sunshine Act
Thought leader engagement has the potential to be impacted by provisions within the Physician Payment Sunshine Act (PPSA). This white paper explores ways that brand teams can build strong thought leader relationships while remaining compliant with these new regulations.
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.
Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.